Hospital
Sparks Family Hospital INC
Sparks Family Hospital INC was paid $7.64M by Medicaid between Jan 2018 and Dec 2024, across 165 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoSPARKS FAMILY HOSPITAL INC
SPARKS, NV 89434
SPARKS, NV 89434
33aNPI1548250582assigned 10/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.64M
24GClaims462,034
24DCodes billed165
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#19 of 36
Median peer was paid$7.64M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,630 | $574K | |
| 2019 | 93,535 | $1.41M | |
| 2020 | 67,886 | $1.11M | |
| 2021 | 74,996 | $1.10M | |
| 2022 | 68,763 | $1.18M | |
| 2023 | 66,310 | $1.25M | |
| 2024incomplete | 46,914 | $1.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 17,040 | 13,820 | $1.44M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 15,019 | 12,952 | $1.21M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 18,455 | 15,535 | $904K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 3,897 | 3,211 | $821K |
| G0378 | Hospital observation service, per hour | 4.6% | 2,962 | 2,059 | $352K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 2,704 | 2,241 | $199K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 5,740 | 1,847 | $175K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 4,960 | 4,479 | $159K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 1,042 | 839 | $158K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 11,107 | 8,691 | $148K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.6% | 4,161 | 1,641 | $125K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 1,798 | 1,551 | $121K |
153 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.6% | 656 | $120K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.5% | 489 | $115K |
| 80053 | Comprehensive metabolic panel | 1.1% | 24,833 | $81K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 3,499 | $79K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 8,240 | $77K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,348 | $75K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,901 | $67K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,878 | $65K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,536 | $60K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,531 | $56K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,712 | $55K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,063 | $49K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,554 | $48K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,631 | $46K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,035 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,589 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,565 | $35K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,031 | $30K |
| 84484 | <1% | 11,123 | $29K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,885 | $28K |
| 36415 | Collection of venous blood by venipuncture | <1% | 35,454 | $27K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 213 | $25K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,133 | $24K |
| 0450 | Emergency room services | <1% | 504 | $23K |
| 94060 | <1% | 599 | $21K | |
| 83690 | <1% | 9,753 | $21K | |
| 93971 | <1% | 373 | $19K | |
| 94726 | <1% | 593 | $19K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,528 | $18K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,165 | $18K |
| 94729 | <1% | 594 | $16K | |
| 84703 | <1% | 5,436 | $15K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 488 | $14K |
| 83880 | <1% | 1,823 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 944 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 939 | $12K |
| 96376 | <1% | 2,069 | $11K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 186 | $11K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,898 | $11K |
| 73630 | <1% | 796 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,415 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,246 | $10K |
| 81001 | <1% | 10,137 | $10K | |
| 83605 | <1% | 3,478 | $10K | |
| 73610 | <1% | 605 | $9K | |
| 97162 | <1% | 238 | $9K | |
| 87430 | <1% | 1,653 | $8K | |
| 97161 | <1% | 263 | $8K | |
| 73564 | <1% | 474 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,621 | $8K |
| 81025 | <1% | 3,770 | $8K | |
| 87070 | <1% | 2,717 | $8K | |
| 93017 | <1% | 746 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 415 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,068 | $7K |
| 87040 | <1% | 2,382 | $7K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 275 | $7K |
| 72100 | <1% | 806 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,910 | $6K |
| 73130 | <1% | 402 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 943 | $6K |
| 73030 | <1% | 316 | $6K | |
| 80061 | Lipid panel | <1% | 1,645 | $6K |
| 87186 | <1% | 2,316 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 44 | $5K |
| 85379 | <1% | 1,499 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,710 | $5K |
| 90715 | <1% | 259 | $5K | |
| 83735 | <1% | 2,689 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 351 | $4K |
| 85610 | <1% | 4,480 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,654 | $3K |
| 84702 | <1% | 645 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 56 | $3K |
| 76801 | <1% | 57 | $3K | |
| 87077 | <1% | 1,357 | $3K | |
| 81003 | <1% | 4,867 | $3K | |
| 85730 | <1% | 2,542 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,242 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,264 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,906 | $2K |
| 84439 | <1% | 857 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,753 | $2K |
| 85027 | <1% | 1,185 | $2K | |
| 82962 | <1% | 6,222 | $2K | |
| 73110 | <1% | 100 | $2K | |
| 71250 | <1% | 22 | $2K | |
| 74018 | <1% | 184 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,889 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,349 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| 74022 | <1% | 52 | $1K | |
| 87561 | <1% | 76 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 338 | $1K |
| 87899 | <1% | 319 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 668 | $1K |
| 86140 | <1% | 767 | $1K | |
| 87205 | <1% | 1,032 | $1K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,696 | $829.16 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,595 | $788.35 |
| 10060 | <1% | 12 | $710.42 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,917 | $704.21 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 501 | $664.31 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $628.46 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 956 | $603.94 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 109 | $598.51 |
| 86901 | <1% | 755 | $596.33 | |
| 86900 | <1% | 738 | $586.37 | |
| 85652 | <1% | 835 | $584.37 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $553.24 |
| 87210 | <1% | 333 | $521.10 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,106 | $439.79 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 119 | $438.56 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,473 | $368.95 |
| 82803 | <1% | 70 | $349.14 | |
| 80076 | <1% | 138 | $334.90 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,858 | $299.48 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $294.50 |
| 73502 | <1% | 13 | $278.79 | |
| 73090 | <1% | 16 | $204.38 | |
| 87420 | <1% | 35 | $200.81 | |
| G0008 | Administration of influenza virus vaccine | <1% | 33 | $139.20 |
| 97165 | <1% | 23 | $136.68 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 407 | $129.07 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 90 | $127.56 |
| 72040 | <1% | 34 | $126.60 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 30 | $105.22 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 120 | $104.42 |
| 86850 | <1% | 102 | $83.40 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 243 | $79.02 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 52 | $76.57 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 500 | $66.02 |
| 90686 | <1% | 33 | $52.45 | |
| 82550 | <1% | 27 | $44.35 | |
| 82075 | <1% | 16 | $41.51 | |
| 84100 | <1% | 36 | $21.95 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 29 | $21.30 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 38 | $20.60 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 15 | $19.48 |
| 82272 | <1% | 18 | $19.43 | |
| 87081 | <1% | 16 | $9.15 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 47 | $1.64 |
| A9270 | Non-covered item or service | <1% | 12,113 | $0.47 |
| C1769 | Guide wire | 0% | 17 | $0.00 |
| 72020 | 0% | 129 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 17 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 291 | $0.00 |
| 0353U | 0% | 276 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 103 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 59 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.